Jack Xie

Jack Xie

Head of Nonclinical Safety China

Janssen China R & D Center

Why I'm a JPAL

Work with people with great ideas and passions. Provide expert opinion to start up companies

Bio

Jack Xie currently is the Head of Nonclinical Safety (NCS) China for Janssen Research Development to oversee multiple functions including toxicology, Pathology, DMPK, and Clinical Bioanalysis. He is a member of Senior Leadership Team of Janssen China R&D and Scientific Affairs and a member of global NCS Leadership Team. He also serves as a council member of Chinese Society of Toxicology (CSOT) and the Chair of Nonclinical Expert Working Group of RDPAC (R&D-based Pharmaceutical Association Committee).
Before joining Janssen in 2019, he was the Site Head of Pharmaceutical Sciences in Roche Innovation Center Shanghai with the executive responsibilities of multi functions including toxicology, DMPK, investigative safety, Bioanalysis, Biomarker, and clinical pharmacology. He was a member of Roche China R&D Leadership Team and a member of Roche Global Translational Safety Committee, which is a governance body to review and endorse all EIH programs in different therapeutic areas. Prior to joining Roche, Jack was a regulatory toxicologist in Targacept, Inc, a bio-pharmaceutical company in Winston Salem, North Carolina. Under his leadership, the advancement of numerous molecules from discovery to the clinic has been supported in different therapeutic diseases areas. Before Targacept, Jack worked as a study director at Toxickon Corp., a non-clinical CRO at Bedford, Massachusetts (USA).
He is a certified toxicologist by the American Board of Toxicology (DABT) and the full member of Society of Toxicology (SOT). He obtained his PhD degree in Pharmacology and Toxicology from University of Rhode Island and his Master/bachelor’s degrees in pharmacology from Peking University.